Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23


The ESMO Colloquia are innovative sessions within the congress programme that bring together top experts to discuss evolving areas of interest to the oncology community.

The Colloquia are organised by ESMO and supported by the industry in a unique collaboration making them the perfect complement to the scientific and education programme of the Congress.

View the complete ELCC Virtual 2021 congress programme

Targeting RET in lung cancer: State of the art in testing and therapeutics 


Saturday, 27 March 2021, 10:30 – 11:50 CET (Central European Time)
Channel 1
View the ESMO Colloquium details

This educational activity is provided by ESMO and co-supported by Lilly Oncology and Thermo Fisher Scientific.

Learning objectives
  • To inform oncologists on testing modalities for RET molecular aberrations in lung cancer, their characteristics and rationale for assaying biological material.
  • To provide an up-to-date review of the effectiveness and feasibility of therapeutics targeting RET in patients with advanced lung cancer.
  • To provide a critical analysis of management strategies with RET-targeting agents by applying the ESMO Guidelines and the MCBS and ESCAT tools, in the context of two clinical cases.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings